Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page

Hospital-Acquired Infections by A. baumannii and Medical Burden
The gram negative bacteria Acinetobacter baumannii is an increasing problem in the health care environment. As an opportunistic pathogen, the bacteria affects mainly highly vulnerable patients particularly those in hospital environments such as those found in intensive care units (ICU) or army field hospitals. It causes a variety of infections such as bacteremia, wound infections, urinary tract infections, meningitis and most of all pneumonia. A. baumannii pneumonia is often observed in mechanically ventilated ICU patients where it is responsible for extremely high mortality rates. Case controlled studies showed that A. baumannii accounts for an attributable mortality of 43%.  An infection with A. baumannii leads to an increased length of stay in the ICU of an average of 15 days.


Current treatments require potent antibiotic regimens, however, natural occurring A. baumannii harbor multidrug resistant genes that can increasingly circumvent these regimens. Resistance mechanisms include reduced expression of drug importing porins, increased expression of various efflux pumps and drug degrading enzymes. As a result, there are reports that more than 36 % of clinical isolates are resistant to carbapenems. Moreover, multidrug resistant A. baumannii isolates have been reported that are resistant to all antibiotics used in the clinic, leaving no adequate treatment today.


Aridis is evaluating the development of therapeutic antibodies against A. baumannii. Previously, a phase II clinical study has shown that a therapeutic antibody can be an effective adjunctive therapy against pneumonia caused by Pseudomonas aeruginosa, a closely related species to A. baumannii. It reduced mortality and decreased length of stay in the ICU. Together with highly qualified academic collaborators, the research team at Aridis has started an antibody target identification program using a proteomic approach. The result is the identification of eight novel putative targets that are expressed during infection in humans and all are highly conserved among all sequenced A. baumannii genomes. An animal pneumonia model for A. baumannii infections showed proof of concept for passive and/or active immunization for most of these targets. Using functional screening assays, Aridis is currently selecting fully human monoclonal antibodies as lead candidates for the treatment of A. baumannii infections.

AR-401: Fully Human Ab To A. baumannii

Acinetobacter Baumannii Bacteria

PHARMACEUTICALS

Breakthrough Therapies for

Antibiotic Resistant Infections

Aridis Home